Postmarket safety events common after FDA approval

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2017年 / 1652卷 / 1期
关键词：
D O I：
10.1007/s40278-017-30148-6
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：11 / 11
相关论文
共 50 条
  • [1] Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer Drugs
    Kim, Janice
    Nair, Abhilasha
    Keegan, Patricia
    Beaver, Julia A.
    Kluetz, Paul G.
    Pazdur, Richard
    Chuk, Meredith
    Blumenthal, Gideon M.
    [J]. ONCOLOGIST, 2020, 25 (04): : 348 - 354
  • [2] FDA enhances oversight of postmarket drug safety
    [J]. Reactions Weekly, 2012, 1400 (1) : 2 - 2
  • [3] IOM Advises FDA on Ethics in Postmarket Safety Trials
    Kuehn, Bridget M.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 304 (06): : 627 - 627
  • [4] Characteristics of Novel Therapeutics and Postmarket Safety Events
    Tanimoto, Tetsuya
    Mori, Jinichi
    Oshima, Yasuo
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (11): : 1067 - 1067
  • [5] Inducing Compliance with Postmarket Studies for Drugs Under FDA's Accelerated Approval Pathway
    Xu, Liang
    Zhao, Hui
    Petruzzi, Nicholas C.
    [J]. M&SOM-MANUFACTURING & SERVICE OPERATIONS MANAGEMENT, 2021, 23 (01) : 170 - 190
  • [6] Safety of FDA approval speed questioned
    不详
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2008, 49 (05) : 29N - 30N
  • [7] Inducing compliance with postmarket studies for drugs under FDA’s accelerated approval pathway
    Xu L.
    Zhao H.
    Petruzzi N.C.
    [J]. Manufacturing and Service Operations Management, 2021, 23 (01): : 170 - 190
  • [8] Pattern of Postmarket Requirements and Commitments and FDA Approval of Novel Therapeutic Agents from 2003 to 2013
    Deshmukh, Anura
    Gomez, Andres
    Kou, Tzuyung D.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 471 - 471
  • [9] Solitaire Flow Restoration Thrombectomy for Acute Ischemic Stroke: Retrospective Multicenter Analysis of Early Postmarket Experience After FDA Approval
    Mokin, Maxim
    Dumont, Travis M.
    Veznedaroglu, Erol
    Binning, Mandy J.
    Liebman, Kenneth M.
    Fessler, Richard D., II
    To, Chiu Yuen
    Turner, Raymond D.
    Turk, Aquilla S.
    Chaudry, M. Imran
    Arthur, Adam S.
    Fox, Benjamin D.
    Hanel, Ricardo A.
    Tawk, Rabih G.
    Kan, Peter
    Gaughen, John R., Jr.
    Lanzino, Giuseppe
    Lopes, Demetrius K.
    Chen, Michael
    Moftakhar, Roham
    Billingsley, Joshua T.
    Ringer, Andrew J.
    Snyder, Kenneth V.
    Hopkins, L. Nelson
    Siddiqui, Adnan H.
    Levy, Elad I.
    [J]. NEUROSURGERY, 2013, 73 (01) : 19 - 25
  • [10] Cardiotoxic safety communications after FDA approval of novel cancer therapies.
    Bonsu, Janice
    Kola-Kehinde, Onaopepo
    Kim, Lisa
    Ruz, Patrick
    Lustberg, Maryam B.
    Brammer, Jonathan Edward
    Addison, Daniel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345